ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42589248

Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.

Juanes-Gusano D and 3 others. Int J Mol Sci, 2026. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies. Papers, record 42589248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42589248

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-15
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Juanes-Gusano DDianahttps://orcid.org/0000-0001-5818-7371
2Fernández-Roldán BBeatrizhttps://orcid.org/0009-0002-1528-466X
3Coveñas RRafaelhttps://orcid.org/0000-0001-5677-8266
4Hijazi MMaruanhttps://orcid.org/0000-0003-0861-7577

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GlioblastomaMajor topic
Blood-Brain BarrierMajor topic
Signal TransductionMajor topic
Protein Kinase InhibitorsMajor topic
Brain NeoplasmsMajor topic
Antineoplastic AgentsMajor topic
Humans
Animals
Molecular Targeted Therapy

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
PID2021-128119OA-I00Ministerio de Ciencia, Innovación y UniversidadesPubMed
CNS2024-154392Ministry of Science and InformationPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References217

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,467,546Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies.Arch Pharm (Weinheim)2025https://conductscience.org/library/papers/34467546PubMed
222,155,252A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo.Biochem Biophys Res Commun2012https://conductscience.org/library/papers/22155252PubMed
322,571,662New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.Curr Pharm Des2012https://conductscience.org/library/papers/22571662PubMed
427,660,467Sunitinib: the antiangiogenic effects and beyond.Onco Targets Ther2016https://conductscience.org/library/papers/27660467PubMed
522,837,387Transforming fusions of FGFR and TACC genes in human glioblastoma.Science2012https://conductscience.org/library/papers/22837387PubMed
622,621,397Irreversible protein kinase inhibitors: balancing the benefits and risks.J Med Chem2012https://conductscience.org/library/papers/22621397PubMed
718,852,116Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther2008https://conductscience.org/library/papers/18852116PubMed
828,965,185Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.Invest New Drugs2018https://conductscience.org/library/papers/28965185PubMed
938,563,164Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.Expert Rev Mol Med2024https://conductscience.org/library/papers/38563164PubMed
1025,800,004High levels of c-Met is associated with poor prognosis in glioblastoma.J Neurooncol2015https://conductscience.org/library/papers/25800004PubMed

1 to 10 of 217

See all 217 references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42,883,815Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: Fourth Edition".Int J Mol Sci2026https://conductscience.org/library/papers/42883815PubMed
42,737,836Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications.Int J Mol Sci2026https://conductscience.org/library/papers/42737836PubMed

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15,243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
BCRP1644,079PubTator's text mininghttps://conductscience.org/library/genes/644079NCBI Gene
SLC7A58,140PubTator's text mininghttps://conductscience.org/library/genes/8140NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42589248

GET https://conductscience.org/api/papers/v1/42589248/references?page=2

API referenceFor AI assistants